Mai H. Le

Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors

L. Coussens, H. Rugo, N. Sharma, 2019, Therapeutic advances in medical oncology.

Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.

S. Jagannath, A. Jakubowiak, R. Vij, 2009 .